{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:13:41Z","timestamp":1789708421340,"version":"4.0.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Maintenance antiretroviral therapy with combination of two injectable long-acting drugs, cabotegravir and rilpivirine, is a new strategy addressing the challenges of daily adherence to oral pills that has shown non-inferior efficacy to standard of care therapy in patients with suppressed HIV-infection. Patients co-infected with hepatitis B virus (HBV) are not eligible for this dual therapy since it has no activity against HBV, but this strategy should also be restricted to patients with anti-HBs antibodies since people with HIV are still at risk of HBV acquisition due to high risk behavior and since HBV vaccination does not always elicit anti-HBs antibodies, as highlighted in the case report below.<\/jats:p>","DOI":"10.1093\/ofid\/ofaa367","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T15:04:37Z","timestamp":1601046277000},"source":"Crossref","is-referenced-by-count":25,"title":["Acute Hepatitis B Infection After a Switch to Long-Acting Cabotegravir and Rilpivirine"],"prefix":"10.1093","volume":"7","author":[{"given":"Claire","family":"Pintado","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Saint-Louis Hospital, University of Paris Diderot, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Delaugerre","sequence":"additional","affiliation":[{"name":"Department of Virology, Saint-Louis Hospital, University of Paris Diderot, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Saint-Louis Hospital, University of Paris Diderot, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"2020092511043435300_CIT0001","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"2020092511043435300_CIT0002","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"2020092511043435300_CIT0003","doi-asserted-by":"crossref","first-page":"e0190487","DOI":"10.1371\/journal.pone.0190487","article-title":"Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain","volume":"13","author":"Kerrigan","year":"2018","journal-title":"PLoS One"},{"key":"2020092511043435300_CIT0004","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/jama.2011.351","article-title":"Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial","volume":"305","author":"Launay","year":"2011","journal-title":"JAMA"},{"key":"2020092511043435300_CIT0005","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3748\/wjg.v24.i11.1216","article-title":"Differing profiles of people diagnosed with acute and chronic hepatitis B virus infection in British Columbia, Canada","volume":"24","author":"Binka","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2020092511043435300_CIT0006","doi-asserted-by":"crossref","first-page":"ofy251","DOI":"10.1093\/ofid\/ofy251","article-title":"Hepatitis B virus (HBV) infection and re-activation during nucleos(t)ide reverse transcriptase inhibitor-sparing antiretroviral therapy in a high-HBV endemicity setting","volume":"5","author":"Abdullahi","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2020092511043435300_CIT0007","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/QAD.0000000000000180","article-title":"Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection","volume":"28","author":"Heuft","year":"2014","journal-title":"AIDS"},{"key":"2020092511043435300_CIT0008","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/infdis\/jiw195","article-title":"Dually active HIV\/HBV antiretrovirals as protection against incident hepatitis B infections: potential for prophylaxis","volume":"214","author":"Shilaih","year":"2016","journal-title":"J Infect Dis"},{"key":"2020092511043435300_CIT0009","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1089\/aid.2017.0070","article-title":"Hepatitis B virus vaccination in HIV: immunogenicity and persistence of seroprotection up to 7 years following a primary immunization course","volume":"34","author":"Nicolini","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2020092511043435300_CIT0010","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1473-3099(15)00220-0","article-title":"Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial","volume":"15","author":"Rey","year":"2015","journal-title":"Lancet Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/9\/ofaa367\/33792370\/ofaa367.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/9\/ofaa367\/33792370\/ofaa367.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T15:04:42Z","timestamp":1601046282000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa367\/5911617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa367","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,9,1]]},"article-number":"ofaa367"}}